雅各臣科研製藥(02633.HK)預計年度純利同比增長超10%
格隆匯5月26日丨雅各臣科研製藥(02633.HK)公佈,集團預期截至2025年3月31日止年度錄得來自持續經營業務的溢利較截至2024年3月31日止年度增加超過40%。
來自持續經營業務的年內溢利大幅增加主要歸因於專科藥物及整體非專利藥業務業績理想,以及新獲授權產品和新產品強勁推出所帶來的收益貢獻。此外,生產設施經營槓桿的提升以及因有效成本控制措施而節省的相應開支,亦推動相關增長。
由於在2023年8月向股東實物分派健倍苗苗(保健)有限公司(股份代號:2161)(「健倍苗苗」)股份作爲特別股息後,公司不再將健倍苗苗及其附屬公司的業績於財務報表綜合入賬。因此,預期2025財年公司權益持有人應佔溢利較截至2025年3月31日止年度增加超過10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.